Drug intelligence / Profile preview

BST BIO AXL inhibitor

Development stage: Preclinical
Lead developer: BSTBIO
Modality: Small Molecules

Overview

BST BIO (Bavarian Systems and Technologies GmbH) is developing small-molecule kinase inhibitors that specifically target the AXL receptor tyrosine kinase. AXL is a member of the TAM (Tyro3, Axl, Mer) receptor family and is frequently overexpressed or activated in various malignancies, where it promotes epithelial-to-mesenchymal transition (EMT), tumor cell survival, metastasis, and resistance to chemotherapy and targeted therapies. By inhibiting AXL signaling, these compounds aim to suppress tumor progression and overcome drug resistance in a variety of solid tumors. The program is currently in the preclinical stage of development.

Other names: AXL small molecule inhibitor (BST BIO)

Targets

AXL (AXL receptor tyrosine kinase)

Beyond the preview

Go deeper on BST BIO AXL inhibitor.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BST BIO AXL inhibitor.

Explore the full profile